Clinical vertebral fractures · pPostmenopausal women at higher risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Non‐vertebral fractures · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day probably leads to lower non‐vertebral fractures compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.8 [0.72, 0.9]
Studies not reported
Moderate
Hip Fracture · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day may leads to lower hip fractures compared with placebo (low certainty).
1 finding from 1 review
RR 0.73 [0.56, 0.94]
Studies not reported
Low
Symptoms of opioid withdrawal in the medium term · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in symptoms of opioid withdrawalfin the medium termb compared with higher doses (low certainty).
1 finding from 1 review
Serious adverse eventsg · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in serious adverse eventsg compared with higher doses (low certainty).
1 finding from 1 review
Adverse events · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in adverse events compared with higher doses (low certainty).
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in laxation response: risk of spontaneous rescue‐free bowel… compared with higher dose (low certainty).
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
It is very uncertain whether methylnaltrexone lower dose changes laxation response: risk of spontaneous rescue‐free bowel… compared with higher dose (very low certainty).
1 finding from 1 review
Laxation response: patient assessment of change in bowel status at the end of trial · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in laxation response: patient assessment of change in bowel statusgat… compared with higher dose (low certainty).
1 finding from 1 review
Symptoms of opioid withdrawal in the medium term · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in symptoms of opioid withdrawal in the medium term compared with higher dose (low certainty).
1 finding from 1 review
Serious adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in adverse events compared with higher dose (low certainty).
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine may leads to lower laxation response: risk of spontaneous rescue‐free bowel movements… compared with higher doses (low certainty).
1 finding from 1 review
Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endometrial histology · young women with Turner syndrome who have completed pubertal induction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Uterine perfusion · young women with Turner syndrome who have completed pubertal induction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reproductive outcomes · young women with Turner syndrome who have completed pubertal induction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · young women with Turner syndrome who have completed pubertal induction
1 finding from 1 review
Uterine volume (cm³) · young women with Turner syndrome who have completed pubertal induction
2 findings from 1 review